Jing Wang

Are you Jing Wang?

Claim your profile

Publications (2)4.57 Total impact

  • Source
    Article: Development of an antisense RNA delivery system using conjugates of the MS2 bacteriophage capsids and HIV-1 TAT cell-penetrating peptide.
    Baojun Wei, Yuxiang Wei, Kuo Zhang, Jing Wang, Ruihuan Xu, Sien Zhan, Guigao Lin, Wei Wang, Min Liu, Lunan Wang, Rui Zhang, Jinming Li
    [show abstract] [hide abstract]
    ABSTRACT: RNA-based therapeutic strategies are used widely due to their highly specific mode of action. However, the major obstacle in any RNA-based therapy is cellular delivery and stability in the cells. The self-assembly of the MS2 bacteriophage capsids has been used to develop virus-like particles (VLPs) for drug delivery. In this study, we utilized the heterobifunctional crosslinker, sulfosuccinimidyl-4-(p-maleimidophenyl)-butyrate (sulfo-SMPB), to conjugate the human immunodeficiency virus-1 (HIV-1) Tat peptide and MS2 VLPs; the antisense RNA against the 5'-untranslated region (UTR) and the internal ribosome entry site (IRES) of the hepatitis C virus (HCV) was packaged into these particles by using a two-plasmid coexpression system. The MS2 VLPs conjugated with the Tat peptide were then transferred into Huh-7 cells containing an HCV reporter system. The packaged antisense RNA showed an inhibitory effect on the translation of HCV. This paper describes our initial results with this system using the Tat peptide.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 10/2008; 63(4):313-8. · 2.24 Impact Factor
  • Article: Construction of armored RNA containing long-size chimeric RNA by increasing the number and affinity of the pac site in exogenous rna and sequence coding coat protein of the MS2 bacteriophage.
    Baojun Wei, Yuxiang Wei, Kuo Zhang, Changmei Yang, Jing Wang, Ruihuan Xu, Sien Zhan, Guigao Lin, Wei Wang, Min Liu, Lunan Wang, Rui Zhang, Jinming Li
    [show abstract] [hide abstract]
    ABSTRACT: To construct a one-plasmid expression system of the armored RNA containing long chimeric RNA by increasing the number and affinity of the pac site. The plasmid pET-MS2-pac was constructed with one C-variant pac site, and then the plasmid pM-CR-2C containing 1,891-bp chimeric sequences and two C-variant pac sites was produced. Meanwhile, three plasmids (pM-CR-C, pM-CR-2W and pM-CR-W) were obtained as parallel controls with a different number and affinity of the pac site. Finally, the armored RNA was expressed and purified. The armored RNA with 1,891 bases target RNA was expressed successfully by the one-plasmid expression system with two C-variant pac sites, while for one pac site, no matter whether the affinity was changed or not, only the 1,200 bases target RNA was packaged. It was also found that the C-variant pac site could increase the expression efficiency of the armored RNA. The armored RNA with 1,891-bp exogenous RNA in our study showed the characterization of ribonuclease resistance and stability at different time points and temperature conditions. The armored RNA with 1,891 bases exogenous RNA was constructed and the expression system can be used as a platform for preparation of the armored RNA containing long RNA sequences.
    Intervirology 02/2008; 51(2):144-50. · 2.34 Impact Factor
Browse more researchers